P3 Health Partners Is Profitable on Paper, Insolvent on the Balance Sheet, and Down 59% in 90 Days
A third straight "profitable" quarter rests on $12 million of reconciliations and a liability release; the equity is telling you what it thinks of the remaining $200 million of "value creation."
PIII · Earnings Call · 2026-11-09
The Beat Is a Reconciliation, Again
P3 Health Partners reported $21 million of Adjusted EBITDA for the third quarter, lifted its full-year midpoint to $100 million, and called it a third consecutive profitable quarter. The stock was down roughly 59% over the prior 90 days into the print, and the whole history is a −99% return from a 2021 peak near $572 a share. The market cap is $13.1 million. That gap between the income statement and the tape is the story, and management handed you the explanation in the second paragraph of the CFO's remarks: approximately $7 million of favorable medical margin from the 2025 CMS ACO reconciliation, and approximately $5 million of non-cash income from a liability release tied to the ACO joint venture.So roughly half of a $21 million headline was accounting. This is not a one-off. On the second-quarter call, Leif Pedersen walked through a $54.4 million Adjusted EBITDA figure and subtracted $45 million of favorable prior period development and payer settlement, with “the payer settlement amount was $41 million. And that did not affect revenue. That only affected medical claims expense.” — Leif Pedersen, CFO · 2026-08-10 He described the first half as “$18 million of embedded EBITDA. And $62 million of prior period settlements that came from Q1 and Q2.” — Leif Pedersen, CFO · 2026-08-10 The first quarter was the same shape at smaller scale — “65% of that $17 million is related to change related to prior year -- favorable prior year development of our reserves and about 35% relates to some payer settlements.” — Leif Pedersen, Chief Financial Officer · 2026-05-14 Four quarters, four prior-period lifts. One thing did change: the word itself. settlement was the single highest-momentum keyword on the August call and has since fallen hardest in the company's own momentum history. On this call the same economic event is called a "2025 CMS ACO reconciliation" and a "liability release." Ben Haynor's housekeeping question surfaced the plumbing anyway: “there was about $13 million of medical expense that actually reduced in the quarter related to that portion of the ACO 2025 settlement.” — Leif Pedersen · 2026-11-09Excluding these and other prior period and non-recurring items, underlying Q3 Adjusted EBITDA was approximately $10 million.
Cost Trend Turns, and Nevada Is the Tell
Aric Coffman's headline claim is real and worth stating plainly: year-to-date Medicare Advantage medical expense is 0.7% below full-year 2025 on a normalized basis, which for a company whose revenue per member is up 18% is genuine margin work.But the quarter turned. Medical expense stepped up sequentially, concentrated in outpatient and professional services, with cardiovascular procedures the largest driver. professional services lands as a brand-new high-momentum keyword this quarter — it was not in the top thirty a quarter ago. And the geography is specific: “we did see probably some of those costs increase more in Nevada than probably other markets, which we are looking deep into, especially in regards to that outpatient utilization and some of the professional services in that market.” — Amir Bacchus · 2026-11-09 Nevada is the same market that has been the named problem child in prior calls, so the $200 million opportunity narrative and the recurring problem are in the same state. The disclosure on trend through the year is where I would press. Pedersen offered “we were at 1.7% favorable on a year-over-year basis. Through Q3, that dropped down to 8.7% favorable on a year-over-year basis. Q3 did show some increased pressure on the MedEx side of the business.” — Leif Pedersen · 2026-11-09 A move from +1.7% to +8.7% favorable is not a drop, and it does not square with the prepared remarks. The sign as transcribed points the wrong way; the direction of travel — roughly ten points of deterioration — is what matters, and it is consistent with everything else on the call. This is a sector-wide conversation, not a P3 invention. medical cost trend and pricing discipline were front and center at Oscar Health this week, and Humana opened with a Stars headwind for next year. P3's own recontracting leverage has leaned on Stars performance and burden of illness documentation for several quarters; the quality improvement cited here — nine-point gains in blood pressure and diabetes control, supplemental data submitted at twice last year's pace — is the operating lever that funds the rate conversation.With peers in our sector reporting medical cost trend of 7% or more, this is a meaningful differentiator for P3.